A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma
NCT02138292
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
27
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
Trametinib (2mg)/Digoxin (.25mg)
Sponsor
University of Texas Southwestern Medical Center